Looking to Invest, Acquire, Licence or Partner?

Autoimmune and inflammatory therapies continue to combat significant unmet patient needs. As validated therapeutic options become more prevalent, treatments in this area are drawing increased interest from biotech companies, pharma, and investors alike.

WHY BIOTECH PARTNER?

Securing strategic investment and partnerships to advance and accelerate biotech pipelines, and ensure long-term sustainability in a tough funding environment

Capitalizing on growing pharma interest in autoimmune and inflammatory therapies, to engage at the right time as landmark deals (e.g., Sanofi’s $1.9B deal with Dren Bio) signal rising momentum in the space

WHY PHARMA & INVESTORS PARTNER?

Addressing a significant unmet need in autoimmunity, to deliver durable treatments beyond symptom management and unlock blockbuster potential in a market affecting 10% of the global population

Prioritizing autoimmunity as the lead indication over oncology increases speed-to-market enabling pharma to outpace competitors with targeted cell-depletion strategies across multiple autoimmune diseases

Stronger preclinical infrastructure and clinical validation enhances the rate of development through now established pathways, enabling the easy growth and diversification of pipelines

EVENT IN NUMBERS

70+

attending companies across modalities so pharma could decide which horse to back in this quickly evolving space

6

big pharma companies across business development, search and evaluation and, immunology research provide a comprehensive opportunity to meet the teams assessing due diligence and asset synergy

1-2-1

meetings bookable via the partnering portal for efficient and high yielding conversations between decision makers

100%

alignment on interests and intentions, increasing the surface area for synergy in research and collaboration goals

Testimonials

“It was extremely valuable to be able to easily connect with immunology specific partnering contacts.”

Seismic Therapeutics

“The curated attendee list was very novel for this type of conference - just the right people for interaction and decision-making.”

Artiva Therapeutics

“The conference panellists were very engaging, and the platform made it easy to schedule 1-to-1 meetings.”

Deerfield Management

"Last year’s inaugural summit stimulated great scientific debate and was an intimate forum for partnering discussions. This year I’m excited for conversations around different novel approaches to B-cell depletion in autoimmune disease."

Artiva Biotherapeutics

View Agenda
REGISTER
To the top